{"entity":{"id":"cba-1205","kind":"drug","name":"CBA-1205","aka":[],"tldr":"CBA-1205 is an experimental humanized afucosylated monoclonal antibody from Chiome Bioscience, in phase 1 trials for advanced solid tumours, hepatocellular carcinoma and melanoma and other cancers.","summary":"CBA-1205 is a humanized afucosylated monoclonal antibody (ADCC enhanced) from Chiome Bioscience. A humanized, afucosylated antibody against DLK-1, made with enhanced antibody-dependent cellular cytotoxicity (ADCC). Its furthest stage is phase 1, for advanced solid tumours, hepatocellular carcinoma, melanoma and paediatric cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1 first-in-human study NCT06636435 recruiting per ClinicalTrials.gov (study start June 2020, first posted October 2024). Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Chiome Bioscience: chiome.co.jp","url":"https://www.chiome.co.jp/en/pipeline/"},{"label":"Chiome Bioscience: chiome.co.jp","url":"https://www.chiome.co.jp/en/pipeline/"},{"label":"Chiome Bioscience: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT06636435"},{"label":"ClinicalTrials.gov: trials of CBA-1205","url":"https://clinicaltrials.gov/search?intr=CBA-1205"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","hcc","melanoma","childhood-cancers","neuroblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["chiome-bioscience"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06636435"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"CBA-1205","modality":"Humanized afucosylated monoclonal antibody (ADCC enhanced)","mechanism":"A humanized, afucosylated antibody against DLK-1, made with enhanced antibody-dependent cellular cytotoxicity (ADCC).","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/cba-1205/","neighbours":{"cancer":[{"id":"childhood-cancers","kind":"cancer","name":"Childhood cancers (all types)","route":"/cancers/childhood-cancers/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"neuroblastoma","kind":"cancer","name":"Neuroblastoma (paediatric)","route":"/cancers/neuroblastoma/"}],"company":[{"id":"chiome-bioscience","kind":"company","name":"Chiome Bioscience","route":"/companies/chiome-bioscience/"}],"trial":[{"id":"nct06636435","kind":"trial","name":"A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer","route":"/trials/nct06636435/"}]}}